Avemar research history
Hullet and Stern analyzed the chemical changes during the fermentation of wheat
germ with yeast.
Nobel laureate Albert Szent-Györgyi, in his Woods Hole laboratory, presumes
that the lack of ascorbic acid and methoxy-substituted benzoquinones is
related to the development of cancer. His idea was that these compounds
also might have primary roles in maintaining immunity.
Máté Hidvégi, professor of biochemistry in
Budapest - based on the ideas of Szent-Györgyi - works on the production of a
natural-based quinone-concentrate. Rita Tömösközi-Farkas, a student of Hidvégi,
who works in the laboratory of Hermann Esterbauer in Graz., joins the research
Lapis and Béla Szende, and Dr. Erzsébet Rásó, all from the Semmelweis Medical
University of Budapest, find that Hidvégi's extract of wheat germ significantly
inhibits, if combined with chemotherapeutic agents prevents malignant tumors
from metastasizing. These results are based on research using several thousand
As a result of further
animal studies they postulate that the extract's immune-reconstructive
properties are primarily responsible for these incredible effects. They also
point out that this agent selectively inhibits adhesion, division of cancer
cells and increases their apoptosis. The experiments of Dr. László Prónai in
Japan show the antioxidant qualities of the extract. Avemar did not prove to be
poisonous in toxicological investigations. The experiments are funded by private
individuals: Mihály Kupa and Ákos Resetár economists.
Máté Hidvégi, László Nagypál and Klára Dési
elaborate the industrial manufacturing technology of the extract. The final
steps are developed in Israel.
Biromedicina - Fist Hungarian Corpoartion for
Cancer Research and Oncology is founded for the further research and launching
Later, Ákos Resetár, CEO of Biromedicina Group announces
acquisition of the frist Hungarian biotech company with GMP drug manufacuring
certificate, ISO, Prima Planta (today: Biropharma).
Avemar's professional presentation in Tel
Aviv and Budapest. Hungarian Ministry of Health approves the distribution of
Avemar as a dietary supplement.
The teams of Dr. Éva Monostori and Prof. Erno Duda, both at the Biological
Research Center at Szeged, start to clear up the mechanism by which Avemar
Prof. Ferenc Jakab et al., at the university
clinics in Budapest, Szeged and Debrecen, find that Avemar in patients with
colon and rectal cancer retards up progression of cancer growth including the
development of metastases. Prof. Ottó Ribári et al., at the Semmelweis Medical
University, experience beneficial effects of the preparation in patients with
head and neck cancer. Prof. Ádám Balogh et al., at Szeged Medical University,
find that Avemar considerably reduces the side effects of chemotherapy. The
latter is reaffirmed by experiments of Prof. Julia Gidáli et al. at the National
Institute of Hematology and Immunology in Budapest. Prof. Géza Bálint et al. at
the National Center of Rheumatology in Budapest, show that the product is
clinically efficient in rheumatoid arthritis. Prof. György Falkay et al. at the
Szeged Medical University, demonstrate the general anti-inflammatory effect of
Avemar. Prof. Attila Zalatnai et al. at the Semmelweis Medical University, prove
the ability of the preparation to prevent cancer. Prof. Yehuda Shoenfeld et al.
at Tel Aviv University show the effectiveness of the product in SLE. Prof.
László Boros et al. at UCLA realize that Avemar inhibits the division of cancer
cells by a mechanism independent of the immune system.
Prof. Anna Tompa et al. in Budapest, show
that Avemar is able to improve the immune system also in patients not having
cancer. Schoenfeld's team realizes that Avemar also inhibits autoimmune
atherosclerosis. Prof. Lev Demidov et al. at the Blohin Oncology Institute in
Moscow, find that Avemar strongly inhibits the development of metastases in
patients with melanoma. Professors Ferenc Jakab, Ádám Balogh and Péter Sápy
prove that Avemar not only holds up progression, but significantly prolongs
survival in advanced colon and rectal cancer. Dr. Zoltán Ajkay et al. at the
National Institute of Pulmonology in Budapest, show that the preparation
considerably improves quality of life for patients afflicted by advanced lung
cancer. Dr. Éva Monostori, Prof. Erno Duda, Dr. Endre Kiss-Tóth and Prof. Steven
Dower from the University of Sheffield publish Avemar's hypothetical mechanism
of action. Based on comparative laboratory studies of Avemar and anti-cancer
drugs, Prof. Marta Cascante at Barcelona University and Prof. László Boros at
UCLA presume that Avemar also might be of use for treating stage IV. cancer
patients. By synthesis of the results Dr. András Telekes at the National
Institute of Oncology in Budapest, outlines Avemar's complex mechanism of
Avemar is registered in
Hungary with an authority approved label as a "medical nutriment for cancer
patients". CNN comments the event as "cancer reserch in Hungary has reached a
Lajos Koltai, Academy Award-Winner cameraman makes the first
television advertisement for the Avemar Project. Faces of the Italian
Renessaince take part in the communication to medical professionals.
Avemar gets approved label with
cancer claims in the Czech Republic and in Bulgaria. At this time Avemar is
available in 10 markets around the world.
"A medical nutriment has
supportive value in the treatment of colorectal cancer." - First time clinical
data of a medical nutriment are published in British Journal of Cancer.
Launching of www.avemar.com.